Effect of IFN-γ on Innate Immune Cells
Chronic Granulomatous Disease
About this trial
This is an interventional basic science trial for Chronic Granulomatous Disease focused on measuring Interferon-gamma, innate immunity
Eligibility Criteria
Inclusion Criteria:
- Healthy adults over the age of 18 years up to 60 years.
- At time of screening subject is well and healthy;
- Acute infections resolved;
- Subject off treatment medications;
- No diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications.
- Non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator.
Exclusion Criteria:
- Pregnancy.
- History of current infection;
- Two weeks from most recent intercurrent infection;
- History of recurrent infections or immunodeficiency.
Sites / Locations
- University of Colorado Denver, Anschutz Medical Campus
Arms of the Study
Arm 1
Other
SD or SS
In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.